Peer-Reviewed Publication
Am J Respir Crit Care Med2026June 26, 2026Journal Article
Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in NSCLC.
Rajender Nandigama1,2, Bassem Ben Cheikh3, Jochen Wilhelm1,4, Nadya Nikulina1,2, Laura V Klotz5, Jamal Nabhanizadeh1,2, Mark Kriegsmann6,7, Marek Bartkuhn1,4, Mario Looso2, Niyati Jhaveri3, Oliver Braubach3, Albrecht Stenzinger6, Martin Reck8, Friedrich Grimminger1,4, Werner Seeger1,2,4, Soni Savai Pullamsetti1,2,4,9, Andreas Weigert10, Thorsten Stiewe1,11, Hauke Winter5, Rajkumar Savai1,2,4,9
1Institute for Lung Health (ILH), Justus Liebig University, Giessen, Germany.
2Max Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim, Germany.
3Akoya Biosciences, Massachusetts, United States.
4Department of Internal Medicine, Member of the DZL, Member of CPI, Justus Liebig University, Giessen, Germany.
5Department of Thoracic Surgery, Thorax clinic at the University Hospital, Heidelberg, Translational Lung Research Center (TLRC), Member of the DZL, Germany, Heidelberg.
6Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
7Centre for Histology, Cytology and molecular pathology Wiesbaden, Wiesbaden, 65199, Germany.
8Department of Thoracic Oncology, Airway Research Center North, Member of the DZL, LungenClinic, Grosshansdorf, Germany.
9Pulmonary Hypertension and Vascular Biology Research Group of Quebec Heart and Lung Institute, Department of Medicine, Laval University, Quebec, Canada.
10Institute of Biochemistry I, Goethe-University, Frankfurt, Germany.
11Philipps-Universität Marburg, Institute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Marburg, Germany.
Abstract
RATIONALE: Only subset of patients with Non-Small Cell Lung Cancer (NSCLC) benefit from immunotherapy and this is partly due to limited understanding of how oncogenic mutations shape the tumor microenvironment (TME).
OBJECTIVES: To define how EGFR and KRAS mutations influence the spatial organization and immune composition of the NSCLC TME.
METHODS: We conducted 38-marker high-plex immunofluores…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans